Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)439.20
  • Today's Change5.20 / 1.20%
  • Shares traded20.22k
  • 1 Year change-2.03%
  • Beta0.9468
Data delayed at least 15 minutes, as of May 17 2022 08:42 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.

  • Revenue in DKK (TTM)15.55bn
  • Net income in DKK3.09bn
  • Incorporated2000
  • Employees6.64k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NZYM B:CPH since
announced
Transaction
value
Synergia Life Sciences Pvt LtdAnnounced30 Nov 202130 Nov 2021Announced-10.11%151.86m
Data delayed at least 15 minutes, as of May 17 2022 08:42 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Imcd NV25.56bn1.54bn55.06bn3.74k35.675.0724.662.153.643.6460.3525.641.156.026.31918,516.106.955.649.717.8221.3820.286.034.650.8114.840.433444.4723.8014.9172.5523.2223.7224.12
Oci NV53.96bn6.32bn55.99bn3.72k8.872.953.051.044.024.0234.3712.120.774612.888.471,952,091.0017.221.8327.232.5831.2520.6522.234.151.3013.680.4298--81.8827.08421.0527.71-19.49--
Arkema SA75.75bn11.15bn61.91bn20.20k5.741.223.960.817319.5219.52133.3491.430.83196.116.31527,324.5012.366.6315.128.0723.9521.7814.857.981.3126.210.323827.6720.744.79325.3324.819.627.91
Chr Hansen Holding A/S8.52bn1.65bn69.80bn3.95k42.555.7128.968.1912.4448.2364.4592.720.35923.466.922,160,046.006.9410.128.8612.7356.5057.4019.3121.610.697411.420.376461.3511.072.57-14.211.5714.8320.14
Umicore SA178.99bn4.61bn69.89bn13.64k14.902.959.730.39052.562.5699.4112.912.778.0513.711,763,651.007.214.8912.038.126.476.512.611.840.883312.690.404935.6116.1518.16374.1927.877.673.83
Brenntag SE117.44bn4.47bn79.81bn17.21k17.872.5211.340.67963.893.89102.2027.561.598.366.67915,705.506.215.519.317.6623.1422.243.903.520.980813.040.398141.7221.946.50-3.904.477.506.67
Akron PAO18.87bn6.43bn81.08bn11.21k11.607.5710.364.301,562.541,562.544,595.302,395.290.73542.9921.09--25.348.4035.9812.1759.9047.3434.4615.831.10--0.448981.994.385.43-86.33-26.953.50-19.73
Yara International ASA139.92bn9.95bn82.58bn17.80k8.331.414.970.590253.3253.32750.87314.171.124.238.5610,765,260.007.572.8110.323.5727.1326.576.783.500.7444--0.3365150.2943.367.93-35.02-9.93-12.0023.39
Evonik Industries AG119.76bn6.46bn86.76bn33.15k13.461.156.060.72441.861.8734.5221.840.72324.877.92487,668.203.993.354.974.0126.4728.765.525.130.800329.420.288979.0822.593.2752.970.00-1.540.3454
Novozymes A/S15.55bn3.09bn97.20bn6.64k38.7110.4921.436.2511.0511.0555.5440.790.66212.424.892,513,907.0013.2015.3617.9320.1356.9557.0319.9321.410.755219.290.386446.706.701.1211.360.62170.39176.58
Akzo Nobel NV73.29bn5.64bn106.38bn32.90k19.052.5612.431.454.134.1853.8430.800.67823.804.02300,274.405.484.027.995.6539.1042.738.086.610.957830.760.478165.0712.390.322329.209.04-14.601.30
PhosAgro PAO46.41bn14.31bn109.41bn25.00k7.64--6.262.361,001.521,001.523,247.01------------16.47--21.0147.7545.8030.8418.21--42.99--91.1565.6317.50665.9916.713.5747.68
Data as of May 17 2022. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK

Institutional shareholders

19.91%Per cent of shares held by top holders
HolderShares% Held
Norges Bank Investment Managementas of 31 Dec 20218.06m3.55%
MFS International (UK) Ltd.as of 28 Feb 20227.35m3.24%
Baillie Gifford & Co.as of 12 May 20226.56m2.89%
The Vanguard Group, Inc.as of 05 May 20225.14m2.26%
BlackRock Fund Advisorsas of 04 May 20223.75m1.65%
Impax Asset Management Ltd.as of 31 Mar 20223.04m1.34%
Harding Loevner LPas of 31 Mar 20223.02m1.33%
Canada Pension Plan Investment Boardas of 31 Mar 20212.87m1.27%
Walter Scott & Partners Ltd.as of 31 Mar 20222.83m1.25%
Handelsbanken Fonder ABas of 30 Apr 20222.63m1.16%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.